Effectiveness of Solution-Focused Therapy for Generalized Anxiety Disorder in Emerging Adults
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
Anxiety disorders are common worldwide, and anxiety and stress symptoms are particularly prevalent among university students in Pakistan. Emerging adulthood is a critical developmental period characterized by significant transitions, identity exploration, and heightened stress, during which Generalized Anxiety Disorder (GAD) can emerge. GAD is characterized by excessive and persistent anxiety and worry related to different areas of life, including work, family, health, or finances. Although conventional psychological therapies are available for such mental health problems, they can be time-consuming and costly. Therefore, shorter and effective psychological interventions are needed. Solution-Focused Therapy (SFT) has been supported by research as an approach in which fewer sessions may be sufficient for improving psychological symptoms. However, there is limited literature on the effectiveness of SFT for emerging adults with anxiety disorders in Pakistan, and the intervention has not been culturally validated for Pakistani emerging adults with GAD.
This study aims to examine the effectiveness of Solution-Focused Therapy for Generalized Anxiety Disorder in emerging adults in Pakistan. The study will use a randomized controlled trial design. Emerging adults aged 18-29 years will first be screened using the Generalized Anxiety Disorder 7-item (GAD-7) Scale to identify participants with mild to moderate levels of GAD. Eligible participants will then be randomly assigned to a treatment group receiving SFT or a waitlist control group. The SFT intervention will be applied to participants with GAD to examine its effectiveness in reducing their anxiety symptoms.
The study will assess changes in GAD symptoms before and after the intervention to determine the effectiveness of SFT among emerging adults with GAD in Pakistan. It is expected that participants receiving SFT will show a decline in GAD symptoms compared with the waitlist control group. The study will provide evidence regarding the effectiveness of a brief and culturally relevant SFT intervention for emerging adults with GAD in the Pakistani context.
Studietype
Registrering (Antatt)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
- Navn: Fariha Hayat, MS
- Telefonnummer: +92 3365288229
- E-post: fariha.hayat87@gmail.com
Studiesteder
-
-
-
Islamabad, Pakistan, 44000
- Rekruttering
- International Islamic University Islamabad (IIUI)
-
Ta kontakt med:
- Dr Nazia Iqbal, Post-doc
- Telefonnummer: +92-51-9019338
- E-post: nazia.iqbal@iiu.edu.pk
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Voksen
Tar imot friske frivillige
Beskrivelse
Inclusion Criteria: Participants with mild to moderate scores of generalized anxiety disorder upon baseline assessment will be included in the study.
Exclusion Criteria: Individuals will be excluded if they reported a diagnosis of psychotic disorder, and those receiving psychotherapy or counseling for anxiety.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Intervention Group (Receiving Solution-Focused Therapy)
Participants in the intervention group will receive Solution-Focused Therapy (SFT) for mild to moderate Generalized Anxiety Disorder.
|
Participants in intervention group will receive Solution-Focused Therapy.
The program includes approximately 6-8 individual sessions (45-60 minutes) covering goal-setting, exception-finding, scaling questions, the miracle question, identification of existing strengths and resources, and construction of solution-focused action steps.
|
|
Ingen inngripen: Control Group (Waitlist Control Group)
Participants in the control group will not receive Solution-Focused Brief Therapy during the active trial period and will instead be assigned to a waitlist condition.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Generalized Anxiety Disorder 7-item (GAD-7)
Tidsramme: Baseline and Week 8
|
The Generalized Anxiety Disorder 7-item (GAD-7) scale assesses severity of anxiety symptoms.
Total scores range from 0 to 21.
Higher scores indicate more severe anxiety symptoms.
|
Baseline and Week 8
|
|
Depression Anxiety Stress Scales - Short Form (DASS-21)
Tidsramme: Baseline and Week 8
|
The Depression Anxiety Stress Scales - Short Form (DASS-21) measures emotional distress.
The total score ranges from 0 to 63 (combining depression, anxiety, and stress subscales).
Higher scores indicate more severe emotional distress.
|
Baseline and Week 8
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Intolerance of Uncertainty Scale - Short Form (IUS-12)
Tidsramme: Baseline and Week 8
|
The Intolerance of Uncertainty Scale - Short Form assesses reactions to ambiguous situations.
Total scores range from 12 to 60. Higher scores indicate a greater intolerance of uncertainty.
|
Baseline and Week 8
|
|
Negative Problem Orientation Questionnaire (NPOQ)
Tidsramme: Baseline and Week 8
|
The Negative Problem Orientation Questionnaire (NPOQ) evaluates dysfunctional cognitive attitudes toward problem-solving.
Total scores range from 12 to 60. Higher scores indicate a more negative problem orientation.
|
Baseline and Week 8
|
|
Difficulties in Emotion Regulation Scale - Short Form (DERS-SF)
Tidsramme: Baseline and Week 8
|
The Difficulties in Emotion Regulation Scale - Short Form (DERS-SF) assesses emotion dysregulation.
Total scores range from 18 to 90.
Higher scores indicate greater difficulty in regulating emotions.
|
Baseline and Week 8
|
|
Brief Resilience Scale
Tidsramme: Baseline and Week 8
|
The Brief Resilience Scale (BRS) measures the ability to recover from stress.
Total scores range from 6 to 30.
Higher scores indicate greater resilience (a better outcome).
|
Baseline and Week 8
|
Samarbeidspartnere og etterforskere
Etterforskere
- Hovedetterforsker: Fariha Hayat, MS, International Islamic University, Islamabad
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- IIUI/ORIC/Bioethics/110-1928
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .